Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII),a multiethnic,multicenter US cohort

Abstract

Objective

The objective of this report is to determine the impact of remission and low disease activity state (LDAS) on damage accrual and mortality in systemic lupus erythematosus (SLE) patients.

Patients and methods

Visits from the Lupus in Minority populations: Nature vs. Nurture (LUMINA) cohort were categorized into remission (Systemic Lupus Activity Measure (SLAM) score = 0 and prednisone ≤ 5 mg/day and no immunosuppressants), LDAS ((not on remission), SLAM score ≤ 3, prednisone ≤ 7.5 mg/day, no immunosuppressants), or neither: active. Remission and LDAS visits were combined because of the relatively small number of remission visits. Their impact on damage accrual and mortality were examined by Poisson and logistic multivariable regressions adjusting for variables known to affect these outcomes.

Results

A total of 3879 visits for 558 patients (28% Caucasian, 37% African descent, 35% Hispanic) were studied. These visits corresponded to 71 in remission, 585 in LDAS, and 3223 active. The longer the percentage of time the patients were in remission/LDAS, the less damage accrual observed (rate ratio 0.1773 (95% confidence interval (CI) 0.1216 to 0.2584) p < 0.0001). A trend was observed in terms of mortality although statistical significance was not reached (odds ratio 0.303 (95% CI 0.063 to 1.456), p = 0.1360).

Conclusions

The longer the patient's state on Remission/LDAS, the less damage accrual that occurs. The protective effect on mortality was not statistically significant.

Keywords

Damage low disease activity lupus mortality remission

Get full access to this article

View all access options for this article.

References

van Vollenhoven

Mosca

Bertsias

et al.

Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis 2014; 73: 958–967.

van Vollenhoven

Voskuyl

Bertsias

et al.

A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017; 76: 554–561.

Franklyn

Lau

Navarra

et al.

Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 2016; 75: 1615–1621.

Ugarte-Gil

Wojdyla

Pons-Estel

et al.

Remission and low disease activity status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). Ann Rheum Dis 2017; 76: 2071–2074.

Mok

Tse

Chan

. Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus. Ann Rheum Dis 2017; 76: 1420–1425.

Polachek

Gladman

Urowitz

. Defining low disease activity in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2017; 69: 997–1003.

Tsang-A-Sjoe

Bultink

Heslinga

Voskuyl

. Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology (Oxford) 2017; 56: 121–128.

Zen

Iaccarino

Gatto

et al.

The effect of different durations of remission on damage accrual: Results from a prospective monocentric cohort of Caucasian patients. Ann Rheum Dis 2017; 76: 562–565.

Zen

Iaccarino

Gatto

et al.

Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 2018; 77: 104–110.

10.

Petri

Magder

. Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort. Arthritis Rheumatol 2018; 70: 1790–1795.

11.

Tani

Vagelli

Stagnaro

Carli

Mosca

. Remission and low disease activity in systemic lupus erythematosus: An achievable goal even with fewer steroids? Real-life data from a monocentric cohort. Lupus Sci Med 2018; 5: e000234.

12.

Piga

Floris

Cappellazzo

et al.

Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis Res Ther 2017; 19: 247.

13.

Alarcón

Roseman

Bartolucci

et al.

Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998; 41: 1173–1180.

14.

Liang

Socher

Larson

Schur

. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107–1118.

15.

Gladman

Ginzler

Goldsmith

et al.

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369.